Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis

Cytokine

Volumn 75, Issue 2, 2015, Pages 222-227

  Takeshita, Masaru ^a   Suzuki, Katsuya ^a   Kikuchi, Jun ^a   Izumi, Keisuke ^a   Kurasawa, Takahiko ^a   Yoshimoto, Keiko ^a   Amano, Koichi ^b   Takeuchi, Tsutomu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Etanercept; Infliximab; Interferon gamma; Interleukin 6; Rheumatoid arthritis

Indexed keywords

CYTOKINE; ETANERCEPT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 6R; INTERLEUKIN 8; LYMPHOTOXIN; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CYTOKINE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CHEMILUMINESCENCE IMMUNOASSAY; DISEASE ACTIVITY; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; BLOOD; MIDDLE AGED;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; ETANERCEPT; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; RECEPTORS, CYTOKINE;

EID: 84939772826     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.04.011     Document Type: Article

References (37)

1. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7:429-442.
2. McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219.
3. Singh J.A., Christensen R., Wells G.A., et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009, 181:787-796.
4. Smolen J.S., Landewe R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014, 73:492-509.
5. Ma X., Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep 2013, 1:177-184.
6. Furst D.E., Wallis R., Broder M., Beenhouwer D.O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006, 36:159-167.
7. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
8. Calmon-Hamaty F., Combe B., Hahne M., Morel J. Lymphotoxin alpha stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. Cytokine 2011, 53:207-214.
9. Buch M.H., Conaghan P.G., Quinn M.A., et al. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?. Ann Rheum Dis 2004, 63:1344-1346.
10. Neregard P., Krishnamurthy A., Revu S., et al. Etanercept decreases synovial expression of tumour necrosis factor-alpha and lymphotoxin-alpha in rheumatoid arthritis. Scand J Rheumatol 2014, 43:85-90.
11. Takeuchi T., Miyasaka N., Tatsuki Y., et al. Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study. Ann Rheum Dis 2012, 71:1583-1585.
12. Drynda S., Kuhne C., Kekow J. Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor beta levels in rheumatoid arthritis. Ann Rheum Dis 2002, 61:254-256.
13. Fabre S., Dupuy A.M., Dossat N., et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008, 153:188-195.
14. Zivojinovic S.M., Pejnovic N.N., Sefik-Bukilica M.N., et al. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis. J Rheumatol 2012, 39:18-21.
15. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
16. Raza K., Falciani F., Curnow S.J., et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther. 2005, 7:R784-R795.
17. Inoue E., Yamanaka H., Hara M., Tomatsu T., Kamatani N. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007, 66:407-409.
18. Sharp J.T., Lidsky M.D., Collins L.C., Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971, 14:706-720.
19. Nishina N., Kaneko Y., Kameda H., Kuwana M., Takeuchi T. Reduction of plasma IL-6 but not TNF-alpha by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. Clin Rheumatol 2013, 32:1661-1666.
20. Ohshima S., Saeki Y., Mima T., et al. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol 1999, 19:305-313.
21. Charles P., Elliott M.J., Davis D., et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999, 163:1521-1528.
22. Takeuchi T., Miyasaka N., Tatsuki Y., et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:1208-1215.
23. van der Heijde D., Klareskog L., Rodriguez-Valverde V., et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006, 54:1063-1074.
24. Elliott M.J., Maini R.N., Feldmann M., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993, 36:1681-1690.
25. Schuerwegh A.J. Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology (Oxford) 2003, 42:541-548.
26. Catrina A.I., Trollmo C., af Klint E., et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005, 52:61-72.
27. Gerards A.H., de Lathouder S., de Groot E.R., Dijkmans B.A., Aarden L.A. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 2003, 42:1189-1196.
28. Yeo L., Toellner K.M., Salmon M., et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis 2011, 70:2022-2028.
29. Maurice M.M., van der Graaff W.L., Leow A., et al. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1999, 42:2166-2173.
30. Zou J., Rudwaleit M., Brandt J., et al. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003, 48:780-790.
31. Ortigosa L.C., Silva L.C., Duarte A.J., Takahashi M.D., Benard G. Infliximab does not lead to reduction in the interferon-gamma and lymphoproliferative responses of patients with moderate to severe psoriasis. Acta Derm Venereol 2014, 94:26-31.
32. Zou J., Rudwaleit M., Brandt J., et al. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003, 62:561-564.
33. Meyer O. Interferons and autoimmune disorders. Joint Bone Spine 2009, 76:464-473.
34. Veys E.M., Menkes C.J., Emery P. A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1997, 40:62-68.
35. Mesko B., Poliska S., Vancsa A., et al. Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease. Genome Med 2013, 5:59.
36. van Baarsen L.G., Wijbrandts C.A., Rustenburg F., et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010, 12:R11.
37. Kennedy W.P., Simon J.A., Offutt C., et al. Efficacy and safety of pateclizumab (anti-lymphotoxin-alpha) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). Arthritis Res Ther 2014, 16:467.